Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450
Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Meier, Florian [verfasserIn] Kontekakis, Antonis [verfasserIn] Schöffski, Oliver [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2012 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: PharmacoEconomics - [S.l.] : Adis, 2003, 10(2012), 2 vom: Juni, Seite 69-85 |
|---|---|
| Übergeordnetes Werk: |
volume:10 ; year:2012 ; number:2 ; month:06 ; pages:69-85 |
| Links: |
|---|
| DOI / URN: |
10.1007/BF03320779 |
|---|
| Katalog-ID: |
SPR033639469 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033639469 | ||
| 003 | DE-627 | ||
| 005 | 20230519134808.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/BF03320779 |2 doi | |
| 035 | |a (DE-627)SPR033639469 | ||
| 035 | |a (SPR)BF03320779-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Meier, Florian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. | ||
| 650 | 4 | |a Adverse Drug Reaction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Esomeprazol |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Escitalopram |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Poor Metabolizer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Extensive Metabolizer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kontekakis, Antonis |e verfasserin |4 aut | |
| 700 | 1 | |a Schöffski, Oliver |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d [S.l.] : Adis, 2003 |g 10(2012), 2 vom: Juni, Seite 69-85 |w (DE-627)689715714 |w (DE-600)2657342-8 |x 1868-677X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2012 |g number:2 |g month:06 |g pages:69-85 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/BF03320779 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2012 |e 2 |c 06 |h 69-85 | ||
| author_variant |
f m fm a k ak o s os |
|---|---|
| matchkey_str |
article:1868677X:2012----::vlainfcnmcaigiduteayyoedutetooy |
| hierarchy_sort_str |
2012 |
| publishDate |
2012 |
| allfields |
10.1007/BF03320779 doi (DE-627)SPR033639469 (SPR)BF03320779-e DE-627 ger DE-627 rakwb eng 610 ASE Meier, Florian verfasserin aut Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. Adverse Drug Reaction (dpeaa)DE-He213 Esomeprazol (dpeaa)DE-He213 Escitalopram (dpeaa)DE-He213 Poor Metabolizer (dpeaa)DE-He213 Extensive Metabolizer (dpeaa)DE-He213 Kontekakis, Antonis verfasserin aut Schöffski, Oliver verfasserin aut Enthalten in PharmacoEconomics [S.l.] : Adis, 2003 10(2012), 2 vom: Juni, Seite 69-85 (DE-627)689715714 (DE-600)2657342-8 1868-677X nnns volume:10 year:2012 number:2 month:06 pages:69-85 https://dx.doi.org/10.1007/BF03320779 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 10 2012 2 06 69-85 |
| spelling |
10.1007/BF03320779 doi (DE-627)SPR033639469 (SPR)BF03320779-e DE-627 ger DE-627 rakwb eng 610 ASE Meier, Florian verfasserin aut Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. Adverse Drug Reaction (dpeaa)DE-He213 Esomeprazol (dpeaa)DE-He213 Escitalopram (dpeaa)DE-He213 Poor Metabolizer (dpeaa)DE-He213 Extensive Metabolizer (dpeaa)DE-He213 Kontekakis, Antonis verfasserin aut Schöffski, Oliver verfasserin aut Enthalten in PharmacoEconomics [S.l.] : Adis, 2003 10(2012), 2 vom: Juni, Seite 69-85 (DE-627)689715714 (DE-600)2657342-8 1868-677X nnns volume:10 year:2012 number:2 month:06 pages:69-85 https://dx.doi.org/10.1007/BF03320779 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 10 2012 2 06 69-85 |
| allfields_unstemmed |
10.1007/BF03320779 doi (DE-627)SPR033639469 (SPR)BF03320779-e DE-627 ger DE-627 rakwb eng 610 ASE Meier, Florian verfasserin aut Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. Adverse Drug Reaction (dpeaa)DE-He213 Esomeprazol (dpeaa)DE-He213 Escitalopram (dpeaa)DE-He213 Poor Metabolizer (dpeaa)DE-He213 Extensive Metabolizer (dpeaa)DE-He213 Kontekakis, Antonis verfasserin aut Schöffski, Oliver verfasserin aut Enthalten in PharmacoEconomics [S.l.] : Adis, 2003 10(2012), 2 vom: Juni, Seite 69-85 (DE-627)689715714 (DE-600)2657342-8 1868-677X nnns volume:10 year:2012 number:2 month:06 pages:69-85 https://dx.doi.org/10.1007/BF03320779 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 10 2012 2 06 69-85 |
| allfieldsGer |
10.1007/BF03320779 doi (DE-627)SPR033639469 (SPR)BF03320779-e DE-627 ger DE-627 rakwb eng 610 ASE Meier, Florian verfasserin aut Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. Adverse Drug Reaction (dpeaa)DE-He213 Esomeprazol (dpeaa)DE-He213 Escitalopram (dpeaa)DE-He213 Poor Metabolizer (dpeaa)DE-He213 Extensive Metabolizer (dpeaa)DE-He213 Kontekakis, Antonis verfasserin aut Schöffski, Oliver verfasserin aut Enthalten in PharmacoEconomics [S.l.] : Adis, 2003 10(2012), 2 vom: Juni, Seite 69-85 (DE-627)689715714 (DE-600)2657342-8 1868-677X nnns volume:10 year:2012 number:2 month:06 pages:69-85 https://dx.doi.org/10.1007/BF03320779 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 10 2012 2 06 69-85 |
| allfieldsSound |
10.1007/BF03320779 doi (DE-627)SPR033639469 (SPR)BF03320779-e DE-627 ger DE-627 rakwb eng 610 ASE Meier, Florian verfasserin aut Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. Adverse Drug Reaction (dpeaa)DE-He213 Esomeprazol (dpeaa)DE-He213 Escitalopram (dpeaa)DE-He213 Poor Metabolizer (dpeaa)DE-He213 Extensive Metabolizer (dpeaa)DE-He213 Kontekakis, Antonis verfasserin aut Schöffski, Oliver verfasserin aut Enthalten in PharmacoEconomics [S.l.] : Adis, 2003 10(2012), 2 vom: Juni, Seite 69-85 (DE-627)689715714 (DE-600)2657342-8 1868-677X nnns volume:10 year:2012 number:2 month:06 pages:69-85 https://dx.doi.org/10.1007/BF03320779 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 AR 10 2012 2 06 69-85 |
| language |
English |
| source |
Enthalten in PharmacoEconomics 10(2012), 2 vom: Juni, Seite 69-85 volume:10 year:2012 number:2 month:06 pages:69-85 |
| sourceStr |
Enthalten in PharmacoEconomics 10(2012), 2 vom: Juni, Seite 69-85 volume:10 year:2012 number:2 month:06 pages:69-85 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Adverse Drug Reaction Esomeprazol Escitalopram Poor Metabolizer Extensive Metabolizer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
PharmacoEconomics |
| authorswithroles_txt_mv |
Meier, Florian @@aut@@ Kontekakis, Antonis @@aut@@ Schöffski, Oliver @@aut@@ |
| publishDateDaySort_date |
2012-06-01T00:00:00Z |
| hierarchy_top_id |
689715714 |
| dewey-sort |
3610 |
| id |
SPR033639469 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033639469</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519134808.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03320779</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033639469</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03320779-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meier, Florian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adverse Drug Reaction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esomeprazol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Escitalopram</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Poor Metabolizer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Extensive Metabolizer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kontekakis, Antonis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schöffski, Oliver</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">[S.l.] : Adis, 2003</subfield><subfield code="g">10(2012), 2 vom: Juni, Seite 69-85</subfield><subfield code="w">(DE-627)689715714</subfield><subfield code="w">(DE-600)2657342-8</subfield><subfield code="x">1868-677X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:69-85</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03320779</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2012</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">69-85</subfield></datafield></record></collection>
|
| author |
Meier, Florian |
| spellingShingle |
Meier, Florian ddc 610 misc Adverse Drug Reaction misc Esomeprazol misc Escitalopram misc Poor Metabolizer misc Extensive Metabolizer Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 |
| authorStr |
Meier, Florian |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)689715714 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1868-677X |
| topic_title |
610 ASE Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 Adverse Drug Reaction (dpeaa)DE-He213 Esomeprazol (dpeaa)DE-He213 Escitalopram (dpeaa)DE-He213 Poor Metabolizer (dpeaa)DE-He213 Extensive Metabolizer (dpeaa)DE-He213 |
| topic |
ddc 610 misc Adverse Drug Reaction misc Esomeprazol misc Escitalopram misc Poor Metabolizer misc Extensive Metabolizer |
| topic_unstemmed |
ddc 610 misc Adverse Drug Reaction misc Esomeprazol misc Escitalopram misc Poor Metabolizer misc Extensive Metabolizer |
| topic_browse |
ddc 610 misc Adverse Drug Reaction misc Esomeprazol misc Escitalopram misc Poor Metabolizer misc Extensive Metabolizer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
PharmacoEconomics |
| hierarchy_parent_id |
689715714 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
PharmacoEconomics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)689715714 (DE-600)2657342-8 |
| title |
Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 |
| ctrlnum |
(DE-627)SPR033639469 (SPR)BF03320779-e |
| title_full |
Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 |
| author_sort |
Meier, Florian |
| journal |
PharmacoEconomics |
| journalStr |
PharmacoEconomics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2012 |
| contenttype_str_mv |
txt |
| container_start_page |
69 |
| author_browse |
Meier, Florian Kontekakis, Antonis Schöffski, Oliver |
| container_volume |
10 |
| class |
610 ASE |
| format_se |
Elektronische Aufsätze |
| author-letter |
Meier, Florian |
| doi_str_mv |
10.1007/BF03320779 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome p450 |
| title_auth |
Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 |
| abstract |
Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. |
| abstractGer |
Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. |
| abstract_unstemmed |
Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
2 |
| title_short |
Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450 |
| url |
https://dx.doi.org/10.1007/BF03320779 |
| remote_bool |
true |
| author2 |
Kontekakis, Antonis Schöffski, Oliver |
| author2Str |
Kontekakis, Antonis Schöffski, Oliver |
| ppnlink |
689715714 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/BF03320779 |
| up_date |
2024-07-03T19:24:11.788Z |
| _version_ |
1803587055034302464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033639469</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519134808.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03320779</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033639469</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03320779-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meier, Florian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluation of economic savings in drug therapy by dose adjustment to polymorphisms in cytochrome P450</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Objective: The cytochrome P450 superfamily is an important enzyme complex which aids in the metabolization of approximately 80% of pharmaceuticals currently on the market. Genetic variation leads to different phenotypes of metabolization: extensive metabolizer (EM), intermediate metabolizer (IM), poor metabolizer (PM) and ultra-rapid metabolizer (UM). Depending on polymorphism, different doses are appropriate. The information about 2D6, 2C9 and 2C19 is especially relevant from an economic point of view. The authors aim to determine how large the economic savings can be for the statutory health insurance by adapting the dose rate according to the CYP450 genotype. Therefore, they explored the top ten groups of the Anatomical Therapeutic Chemical (ATC) Classification System in sales in 2010. Methods: To calculate potential savings, a formula was designed, which includes the relevant agents, the frequency in which polymorphisms occur, the average defined daily doses and their costs, the number of patients, and the average intake period. Results: 36 appropriate agents were identified for calculation. They incurred a total cost of h2.3 billion for the statutory health insurance in 2010. The maximum saving potential lies in the ATC-group of psychoanaleptics, amounting to h96.1 million. Aripiprazol (h948.60), perphenazin (h352.40) and thiordiazin (€319.10) head the list of agents with the best saving potential per patient and treatment phase. Regarding the costs of diagnostic tests (€100 or €300), only four out of eight drugs are cost-covering. Conclusion: Pharmacogenetic testing and subsequent dose optimization is partially efficient. Mainly for agents with high €/DDD (DDD: Defined Daily Dose) and long duration of treatment, positive cost-aspects have been calculated in total or on a per patient basis. For final economic appraisal, further information is needed, such as the effect on adverse drug reaction or synergy effects for multi-medicated patients. Finally, dose optimization based on genetic information is likely to be efficient for several agents.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adverse Drug Reaction</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Esomeprazol</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Escitalopram</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Poor Metabolizer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Extensive Metabolizer</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kontekakis, Antonis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schöffski, Oliver</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">[S.l.] : Adis, 2003</subfield><subfield code="g">10(2012), 2 vom: Juni, Seite 69-85</subfield><subfield code="w">(DE-627)689715714</subfield><subfield code="w">(DE-600)2657342-8</subfield><subfield code="x">1868-677X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:2</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:69-85</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03320779</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">2012</subfield><subfield code="e">2</subfield><subfield code="c">06</subfield><subfield code="h">69-85</subfield></datafield></record></collection>
|
| score |
7.3974915 |